Today: 21 May 2026
D-Wave Quantum stock price rises after insider filings; QBTS traders eye Qubits 2026 next
16 January 2026
2 mins read

D-Wave Quantum stock price rises after insider filings; QBTS traders eye Qubits 2026 next

NEW YORK, Jan 16, 2026, 15:13 EST — During the regular session

  • QBTS climbed 1.1% to $29.03, trading between $28.29 and $30.12 throughout the session
  • CEO and CFO reported tax-related “sell-to-cover” stock sales in new SEC Form 4 filings
  • Investors are closely monitoring developments on the Quantum Circuits deal, alongside D-Wave’s Qubits 2026 event scheduled for Jan. 27–28

Shares of D-Wave Quantum Inc rose 1.1% to $29.03 on Friday afternoon, while the broader market remained mostly flat. Trading ranged from $28.29 to $30.12, with roughly 34 million shares exchanged.

The move followed a batch of insider disclosures that surfaced late Thursday. Around here, even standard filings can spark a trade signal.

Why it matters now: D-Wave occupies a niche spot among publicly traded quantum-computing firms, with its shares often seen as a barometer for investor mood. The company is working to expand beyond its core quantum annealing technology — a method focused on optimization — by pushing further into gate-model systems, the circuit-based design favored in mainstream quantum research.

CEO Alan Baratz disclosed in a Form 4 filing dated Jan. 15 that he sold 35,013 shares on Jan. 14 at a weighted average price of $28.0623. The filing clarified the sale was a “sell-to-cover” move to cover tax withholding on vesting restricted stock units (RSUs), not a discretionary trade. SEC

Chief financial officer John Markovich disclosed a sale of 9,179 shares on Jan. 14, averaging $28.0623 per share, according to a filing. The transaction cited the same tax-withholding “sell-to-cover” reason. SEC

Chief legal officer Diane Nguyen reported selling 20,000 shares through a Rule 10b5-1 plan set up in August, plus an additional 4,519 shares to cover RSU taxes. The 10b5-1 plan is a prearranged trading program designed to limit insider-trading issues.

Quantum stocks remain in focus following Honeywell’s announcement on Wednesday that it intends to take its majority-owned unit Quantinuum public, having confidentially filed draft IPO documents with U.S. regulators. Such IPO chatter typically sends waves through the smaller, pure-play quantum names.

D-Wave disclosed in an earlier SEC filing that on Jan. 6 it agreed to acquire Quantum Circuits for $550 million, with $300 million paid in stock and $250 million in cash, subject to adjustments. The deal awaits U.S. antitrust approval and other closing conditions, and can be called off if not completed by April 6. The stock portion is based on a 10-day volume-weighted average price with a collar, according to the filing.

When D-Wave revealed the deal, Quantum Circuits co-founder Rob Schoelkopf said “fault-tolerant error-corrected quantum computing is within our reach,” suggesting the partnership might accelerate progress. Baratz described the acquisition as a “pivotal milestone” in D-Wave’s dual-track approach. SEC

There’s a clear risk here: the company remains heavily unprofitable. D-Wave posted $8.8 million in revenue against a $143.9 million net loss in 2024, according to Reuters data. Investors will be wary of any hiccup in the Quantum Circuits deal, especially when it comes to financing and cash flow.

Traders are now turning their attention to D-Wave’s Qubits 2026 user conference, scheduled for Jan. 27–28 in Boca Raton, Florida, hoping for updates on the gate-model roadmap and the Quantum Circuits timeline. Baratz emphasized in a conference release that the focus is on “delivering real impact for customers today.” SEC

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Dow dips from record zone as chip bounce meets Fed succession chatter
Previous Story

Dow dips from record zone as chip bounce meets Fed succession chatter

Google stock price: Alphabet Class C (GOOG) slips after-hours on data-sharing court fight — here’s what’s next
Next Story

Google stock price: Alphabet Class C (GOOG) slips after-hours on data-sharing court fight — here’s what’s next

Go toTop